ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS ...
Primary endpoint of safety and tolerability met Anti-viral effect demonstrated and encouraging initial indication of therapeutic effect Results support advancing the programme into a Phase II efficacy study in infants Potential general proof-of-principle …